Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Jim Haynes who wrote (697)	9/13/1999 1:26:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 4474

Thanks Jim. I suppose the ball is in Ariad's court--I'm sure they'll do what every is necessary to keep themselves in the game, further speculation can serve no purpose-- and it probably served no purpose to begin with. I guess we will hear something when it is time--and they don't have to explain themselves until the next quarterly report if they so choose. Still, good communications with the commoners is generous when it happens. I refer folks to the Gene Logic thread, both on Yahoo and here on SI, where Steve Push has been a frequent spokesman for that company. Ariad is a notch smaller than GLGC however, so it is probably a matter of resources--and frustration. Commoners need spoonfeeding sometimes...

To: Jim Haynes who wrote (697)	9/20/1999 9:41:00 PM
From: LLCF	Read Replies (1) \| Respond to of 4474

<if the science is good, there are bigger companies which would pay a premium of the market cap to buy Ariad, > The only thing we have to remember is that a buyer will be buying all outstanding shares, PLUS the shares that the convert holder is entitled to assuming conversion at what .85 now???? Anyone ever find out for sure if there are 5,000 or 10,000 of those bad boys out there??? Anyway your talking about at least 5mill more common the buyer would have to take out, right? DAK